Chargement en cours...
Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting
Trastuzumab has had a major impact on outcomes in HER2-positive breast cancer, but innate or acquired resistance to it is recognized as a problem that can limit its effectiveness. Given its locus of action, the oral tyrosine kinase inhibitor lapatinib would be expected to counteract many of the prop...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
AME Publishing Company
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4115768/ https://ncbi.nlm.nih.gov/pubmed/25083500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2227-684X.2013.09.01 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|